Document is current
Any future updates will be listed below
-
Authors
Eule, Corbin J. https://orcid.org/0000-0002-8430-1040
Warren, Adam
Molina Kuna, Elizabeth
Robin, Tyler P.
Gershman, Boris
Kim, Simon P.
Flaig, Thomas W. https://orcid.org/0000-0001-6145-9040
-
Funding
Funding for this research was provided by:
Robert Rifkin Endowed Chair, William R. Meyn Foundation, Herbert Crane Prostate Cancer Fund
Cancer Center Support Grant
Schramm Foundation
- License Information
-
More Information
Article History
Received: 29 January 2024
Revised: 27 September 2024
Accepted: 22 October 2024
First Online: 21 November 2024
Competing interests
: CJE, EMK, TPR, and SPK have no relevant conflicts of interest to disclose. TWF reports leadership, stock, and other ownership interests in Aurora Oncology; consulting for Seagen and Janssen Oncology; research funding from Novartis, Bavarian Nordic, Dendreon, GTx Janssen Oncology, Medication, Sanofi, Pfizer, Bristol-Myers Squibb, Roche/Genentech, Exelixis, Aragon Pharmaceuticals, Sotio, Tokai Pharmaceuticals, Atrazeneca/MedImmune, Lilly, Astellas Pharma, Agensys, Seagen, La Rocher-Posay, Merck, Seagen, Myovant Sciences, and Criterium; and patents, royalties, and other intellectual property related to 2 patents filed by the University of Colorado related to early-stage bladder cancer treatment and detection (not currently commercialized or in active clinical development).
: This study used a large, deidentified dataset and was determined to be exempt from review by the Colorado Multiple Institutional Review Board, reference 21–3083. Due to the deidentified and retrospective nature of the secondary-use health data, informed consent could not feasibly be obtained.
